Chris Froome hopes a speedy resolution can be reached in the case relating to his adverse analytical finding at last year's Vuelta a Espana, as the four-time Tour de France winner prepares to return to competitive action.
A sample collected from Froome at the 2017 Vuelta, a Grand Tour race the Team Sky rider won, showed elevated levels of the asthma medication salbutamol.
Salbutamol is permitted by World Anti-Doping Agency (WADA) rules without the need for a therapeutic use exemption (TUE) when inhaled up to a limit of 1,600 micrograms over 24 hours.
Froome's adverse finding, double the permitted threshold, does not necessarily constitute a break of the rules and he has not been suspended by the UCI, world cycling's governing body.
Froome and Team Sky have repeatedly denied wrongdoing since news of his adverse finding emerged last December.
On Monday, it was confirmed the Briton will begin his 2018 season next week at the Ruta del Sol in Andalucia.
In a media release announcing the news, Froome stated: "I'm confident that we will be able to get to the bottom of what has happened and I'm working hard with the team to do that.
"Obviously I understand that this situation has created a lot of uncertainty. I completely get why there has been so much interest and speculation.
"I hope that people will appreciate there are limits to what I can say whilst the process is still ongoing but no one is keener than me to move things forward as quickly as possible."
Dave Brailsford, Sky's general manager, added: "We all recognise that these are difficult circumstances but it's important for all sides that this process is conducted fairly before a final conclusion is reached.
"It is a complex situation but we're working as hard as we can with Chris to resolve things as soon as possible."